ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0997

Novel Shared Antibody Specificities in Ro Antibody Negative Sjögren’s Syndrome

Sherri Longobardi1, Constantin Georgescu2, Christina Lawrence3, Charmaine Moya3, Jonathan Wren4, Judith James5, Kathy Sivils3 and A. Darise Farris6, 1Graduate Program in Biological Sciences, University of Oklahoma Health Sciences Center; Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Genes & Human Disease Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Genes & Human Disease Program, Oklahoma Medical Research Foundation, Oklahoma City, 5Oklahoma Medical Research Foundation, Oklahoma City, 6Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City

Meeting: ACR Convergence 2020

Keywords: Autoantibody(ies), autoimmune diseases, B-Cell Targets, Sjögren's Syndrome

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2020

Title: B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Sjögren’s syndrome (SS) is a rheumatic autoimmune disease characterized by focal lymphocytic infiltrates in the lacrimal and salivary glands, severe dry mouth and eyes, pain and debilitation.  Diagnosis requires autoantibodies to ubiquitous Ro antigens or a lip biopsy positive for focal lymphocytic infiltrates. Here we used human proteome arrays to identify novel antibodies in plasma from Ro antibody positive and Ro antibody negative SS patients compared with healthy controls.

Methods: Anti-Ro positive (n=15) and anti-Ro negative (n=15) cases meeting 2016 ACR/EULAR classification criteria for SS were age, race, and sex matched with each other and healthy controls (n=15).  Plasma IgG binding to human proteome arrays containing >19,500 recombinant human proteins representing >80% of the human proteome (HuProt v3.2 arrays, CDI Laboratories) was assessed.  Data were normalized by the Robust Linear Model using the PAA Bioconductor Package in R and log intensity values for each protein generated.  Thresholds of mean + 3SD were established using the controls.  Antigens bound by IgG in at least 4 cases compared to controls were considered significant (p< 0.05, one-tailed Fisher’s exact test).

Results: IgG from Ro positive SS cases significantly bound 42 proteins, including the canonical SS antigens Ro60, Ro52, and La, with an average of 15 specificities per individual. IgG from Ro negative SS cases significantly bound 24 proteins compared to controls, with an average of 7 specificities per individual.  Of the antigens identified, 8 were shared in both the Ro positive and Ro negative groups.  Binding to at least one of these 8 proteins identified 93% of the Ro positive cases and 87% of the Ro negative cases.

Conclusion: A set of 8 novel antigens were bound by plasma IgG in both Ro positive and Ro negative cases.  These antigens may be useful for diagnosing SS without a lip biopsy.


Disclosure: S. Longobardi, None; C. Georgescu, None; C. Lawrence, None; C. Moya, None; J. Wren, None; J. James, None; K. Sivils, None; A. Farris, None.

To cite this abstract in AMA style:

Longobardi S, Georgescu C, Lawrence C, Moya C, Wren J, James J, Sivils K, Farris A. Novel Shared Antibody Specificities in Ro Antibody Negative Sjögren’s Syndrome [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/novel-shared-antibody-specificities-in-ro-antibody-negative-sjogrens-syndrome/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/novel-shared-antibody-specificities-in-ro-antibody-negative-sjogrens-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology